Applicant

↓

Reference Member State (RMS)

↓

Assessment Report

↓

Concerned Member States (CMS)

↓

Comments & Consensus

↓

National Marketing Authorizations

4. National Procedure (NP)

The National Procedure (NP) is used when a pharmaceutical company intends to market a medicinal product in only one European Union (EU) Member State. Unlike the Centralised Procedure (CP), Decentralised Procedure (DCP), or Mutual Recognition Procedure (MRP), the application is submitted directly to the National Competent Authority (NCA) of the selected country.

This route is generally suitable for products that are intended for a limited market or when the applicant does not initially plan to commercialize the product across multiple EU countries.

Key Characteristics

• Application submitted to one Member State only
• Scientific assessment performed by the respective National Competent Authority
• Authorization valid only in the approving country
• Can later serve as the basis for a Mutual Recognition Procedure (MRP)

Comparison of Marketing Authorization Procedures

Step-by-Step Marketing Authorization Approval Process

Although each regulatory pathway differs slightly, the overall Marketing Authorization process follows a structured sequence of scientific and administrative activities.

Product Development

↓

Regulatory Strategy

↓

Dossier Preparation (CTD/eCTD)

↓

Submission

↓

Validation

↓

Scientific Assessment

↓

Questions from Authority

↓

Applicant Responses

↓

Benefit-Risk Evaluation

↓

Positive Opinion

↓

Marketing Authorization Granted

↓

Commercial Launch

↓

Lifecycle Management

Step 1 – Product Development

The approval journey begins during pharmaceutical development. Before preparing a Marketing Authorization Application (MAA), the applicant must generate sufficient scientific evidence demonstrating that the medicinal product consistently meets predefined quality, safety, and efficacy requirements.

Activities Performed

• Formulation development
• Analytical method development
• Manufacturing process development
• Process optimization
• Stability studies
• Packaging qualification
• Bioequivalence or clinical studies
• Risk assessments

Step 2 – Define Regulatory Strategy

An effective regulatory strategy determines the most appropriate approval pathway and legal basis for the product. Strategic planning at an early stage minimizes regulatory risks and avoids unnecessary delays.

Key considerations include:

• Selection of the appropriate authorization procedure
• Choice of Reference Member State (RMS), if applicable
• Eligibility for the Centralised Procedure
• Patent and exclusivity status
• Reference medicinal product selection
• Availability of supporting scientific data

Step 3 – Preparation of the Marketing Authorization Application (MAA)

The Marketing Authorization Application is prepared using the Common Technical Document (CTD) format, which has been harmonized through the International Council for Harmonisation (ICH). Most submissions are now made electronically in the Electronic Common Technical Document (eCTD) format.

Advantages of eCTD

• Standardized dossier structure
• Electronic lifecycle management
• Efficient document navigation
• Reduced paper submissions
• Simplified regulatory review

CTD Structure

Important Documents Included in Module 1

• Application Form
• Cover Letter
• Proof of Fee Payment
• Product Information
• Summary of Product Characteristics (SmPC)
• Package Leaflet (PIL)
• Labelling Artwork
• Risk Management Plan (RMP)
• Environmental Risk Assessment (where applicable)
• Pharmacovigilance System Master File (PSMF) Summary

Step 4 – Submission of the Marketing Authorization Application

Once the dossier has been finalized and internally reviewed, the application is submitted electronically to the relevant authority.

Depending on the procedure selected, submissions may be made to:

• European Medicines Agency (EMA)
• Reference Member State
• National Competent Authority

Electronic validation checks ensure that the submission complies with the required technical standards before scientific assessment begins.

Step 5 – Validation Phase

The validation phase is an administrative review designed to confirm that the dossier is complete and suitable for scientific evaluation.

Validation Activities

• Verification of legal basis
• Completeness of CTD modules
• eCTD technical validation
• Administrative documentation review
• Fee verification
• Confirmation of GMP compliance
• Verification of manufacturing sites
• Review of application forms

Incomplete applications may be placed on hold or rejected until the identified deficiencies are addressed.

Step 6 – Scientific Assessment

Following successful validation, regulatory experts conduct an extensive scientific evaluation of the application. This assessment focuses on determining whether the product demonstrates a positive benefit-risk balance for the intended patient population.

Main Areas Evaluated

• Quality (Chemistry, Manufacturing and Controls)
• Nonclinical Data
• Clinical Data
• Bioequivalence Studies
• Risk Management Plan
• Product Information
• Pharmacovigilance System

Quality Assessment (CMC Review)

The Chemistry, Manufacturing and Controls (CMC) review is one of the most detailed components of the assessment process.

Regulators evaluate:

• Drug substance manufacturing process
• Drug product manufacturing process
• Specifications
• Analytical method validation
• Process validation
• Impurity profiles
• Container closure system
• Stability studies
• Batch analysis
• Good Manufacturing Practice (GMP) compliance

Clinical Assessment

Clinical assessors review available evidence supporting the safety and efficacy of the medicinal product.

Depending on the legal basis, this may include:

• Clinical efficacy studies
• Clinical safety studies
• Bioequivalence studies
• Literature-based evidence
• Published scientific data

Step 7 – Questions from Regulatory Authorities

During scientific assessment, regulators frequently identify areas requiring clarification. These are communicated to the applicant as a formal List of Questions (LoQ) or Request for Further Information (RFI).

Common questions relate to:

• Manufacturing process validation
• Analytical methods
• Stability data
• Impurity qualification
• Specification justification
• Clinical data interpretation
• Risk management measures

Clock Stop Procedure

Once questions are issued, the regulatory assessment timeline is temporarily paused, commonly referred to as a Clock Stop. During this period, the applicant prepares comprehensive responses and any additional supporting documentation requested by the authority.

The assessment resumes after the authority receives and validates the applicant’s responses.

Best Practices for Responding to Regulatory Questions

• Respond to every question individually.
• Provide clear scientific justification supported by data.
• Reference updated CTD sections where applicable.
• Submit revised documents in the correct eCTD lifecycle format.
• Ensure consistency across SmPC, PIL, labeling, and quality documentation.
• Perform an internal quality review before submission.

Step 8 – Benefit-Risk Evaluation

Once all scientific questions have been addressed and the dossier is considered complete, regulatory assessors perform an overall benefit-risk evaluation. This assessment determines whether the therapeutic benefits of the medicinal product outweigh its potential risks for the intended patient population.

The evaluation considers:

• Product quality and manufacturing consistency
• Clinical efficacy
• Safety profile
• Risk management measures
• Pharmacovigilance commitments
• Overall public health impact

A favorable benefit-risk balance is the primary criterion for granting a Marketing Authorization in the European Union.

Step 9 – CHMP Opinion (Centralised Procedure)

For applications submitted through the Centralised Procedure, the Committee for Medicinal Products for Human Use (CHMP) reviews the final assessment reports and adopts a scientific opinion.

The CHMP may issue:

• Positive Opinion
• Negative Opinion
• Request for Additional Information (in exceptional cases)

A positive CHMP opinion recommends that the European Commission grant a Marketing Authorization valid throughout the European Union and European Economic Area (EEA).

Step 10 – European Commission Decision

Following a positive CHMP opinion, the European Commission conducts the final administrative review and issues a legally binding Marketing Authorization Decision.

Once adopted, the authorization permits the medicinal product to be marketed in all EU Member States as well as Iceland, Norway, and Liechtenstein (where applicable through EEA agreements).

Typical Approval Timelines

*Actual approval timelines may vary depending on product complexity, dossier quality, regulatory questions, and applicant response times.

Good Manufacturing Practice (GMP) Compliance

All manufacturing sites involved in the production, testing, packaging, and release of medicinal products must comply with European Good Manufacturing Practice (EU GMP) requirements.

Regulatory authorities may perform GMP inspections before or after approval to verify compliance.

Areas Evaluated During GMP Inspections

• Quality Management System (QMS)
• Personnel training and qualification
• Facility and equipment
• Documentation practices
• Process validation
• Cleaning validation
• Computerized systems
• Data integrity
• Deviation management
• CAPA effectiveness
• Supplier qualification

Qualified Person (QP) Certification

Before each batch of a medicinal product is released for sale within the European Union, it must be certified by a Qualified Person (QP).

The Qualified Person confirms that:

• The batch has been manufactured in accordance with EU GMP.
• The product complies with the approved Marketing Authorization.
• All required testing has been completed successfully.
• Manufacturing and quality records have been reviewed.

Product Information Approved with the Marketing Authorization

The Marketing Authorization includes several key documents that govern the safe use and distribution of the medicinal product.

• Summary of Product Characteristics (SmPC)
• Package Leaflet (PIL)
• Outer and Inner Labeling
• Risk Management Plan (RMP)

These documents must remain consistent with the approved dossier throughout the product lifecycle.

Post-Approval Lifecycle Management

Obtaining a Marketing Authorization is not the end of the regulatory process. Marketing Authorization Holders (MAHs) are responsible for maintaining product compliance throughout its commercial lifecycle.

Post-approval responsibilities include:

• Variation submissions
• Pharmacovigilance reporting
• Periodic Safety Update Reports (PSURs), where applicable
• Renewal applications
• Labeling updates
• Manufacturing site changes
• Ongoing stability studies
• Regulatory inspections

Variation Procedures

Changes to an approved Marketing Authorization are managed through the European Variations Regulation. The type of variation depends on the potential impact of the proposed change.

Marketing Authorization Renewal

Most Marketing Authorizations are initially granted for a period of five years. Before the expiry of this period, the Marketing Authorization Holder must apply for renewal, demonstrating that the product continues to maintain a positive benefit-risk balance.

Following a successful renewal, the authorization is generally granted for an unlimited period unless additional renewal is justified for pharmacovigilance reasons.

The Sunset Clause

Under European pharmaceutical legislation, a Marketing Authorization may cease to be valid if the medicinal product is not placed on the market within three years of approval or if it is withdrawn from the market for a continuous period of three years, unless an exemption is granted on public health grounds.

Common Reasons for Delays in Marketing Authorization Approval

• Incomplete CTD or eCTD submissions
• Poor dossier quality
• Inadequate process validation data
• Insufficient stability data
• Analytical method validation deficiencies
• Bioequivalence study issues
• GMP inspection findings
• Inconsistent labeling or SmPC
• Unresolved data integrity concerns
• Delayed responses to regulatory questions

Best Practices for a Successful Marketing Authorization Application

• Develop a clear regulatory strategy early in development.
• Prepare a complete and technically compliant CTD/eCTD dossier.
• Ensure manufacturing sites maintain EU GMP compliance.
• Conduct comprehensive internal dossier quality reviews.
• Use current EU guidelines and ICH standards.
• Maintain consistency across all submission documents.
• Respond promptly and scientifically to regulatory questions.
• Implement robust lifecycle management and change control processes.

Frequently Asked Questions (FAQs)

1. What is a Marketing Authorization (MA)?

A Marketing Authorization is the official approval that permits a medicinal product to be marketed within one or more European countries after demonstrating acceptable quality, safety, and efficacy.

2. What are the four Marketing Authorization procedures in Europe?

The four procedures are:

• Centralised Procedure (CP)
• Decentralised Procedure (DCP)
• Mutual Recognition Procedure (MRP)
• National Procedure (NP)

3. What is the difference between DCP and MRP?

The Decentralised Procedure is used when a product has not yet been authorized in any Member State, while the Mutual Recognition Procedure is used to extend an existing national authorization to additional Member States.

4. What format is used for European Marketing Authorization submissions?

Applications are prepared using the Common Technical Document (CTD) format and are generally submitted electronically as eCTD sequences.

5. What is the role of the Marketing Authorization Holder (MAH)?

The MAH is responsible for maintaining regulatory compliance, pharmacovigilance activities, product quality, lifecycle management, and post-approval submissions throughout the product’s market life.

Conclusion

The European Marketing Authorization approval process is one of the most comprehensive and scientifically rigorous pharmaceutical regulatory systems in the world. Whether pursuing the Centralised, Decentralised, Mutual Recognition, or National Procedure, applicants must demonstrate that their medicinal products consistently meet the highest standards of quality, safety, and efficacy.

Successful approval depends on careful regulatory planning, preparation of a complete and compliant CTD/eCTD dossier, adherence to EU GMP requirements, timely responses to regulatory questions, and effective lifecycle management after authorization. Organizations that invest in strong regulatory affairs capabilities and robust quality systems are better positioned to achieve timely approvals and maintain long-term compliance across the European market.

Regulatory Disclaimer